Yohan Royer

发表

JAK kinases overexpression promotes in vitro cell transformation

J. Renauld, S. Constantinescu, L. Knoops, 2008, Oncogene.

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.

C. Pecquet, S. Constantinescu, P. Courtoy, 2012, Blood.

Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer.

S. Constantinescu, J. Staerk, Steven O. Smith, 2003, Molecular cell.

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

M. Tomasson, S. Constantinescu, J. Griffin, 2008, Blood.

of the Myc and Pim proto-oncogenes requires a functional FERM domain for transformation and for expression The Jak2V617F oncogene associated with myeloproliferative diseases

S. Constantinescu, J. Griffin, D. Gilliland, 2013 .

Ligand-independent Homomeric and Heteromeric Complexes between Interleukin-2 or -9 Receptor Subunits and the γ Chain*

J. Renauld, S. Constantinescu, L. Knoops, 2008, Journal of Biological Chemistry.

Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and Stability*

S. Constantinescu, P. Courtoy, J. Staerk, 2005, Journal of Biological Chemistry.

Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor α Homodimers*

J. Renauld, S. Constantinescu, M. Tartaglia, 2009, Journal of Biological Chemistry.

JAK2, the JAK2 V617F mutant and cytokine receptors.

W. Vainchenker, J. Staerk, A. Dusa, 2007, Pathologie-biologie.